ProQR Therapeutics N.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ProQR Therapeutics N.V.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
The Dutch biotech has firmed up its finances as its promising pipeline of RNA therapies for rare genetic eye disease starts to move through the clinic.
Partners pioneer approach in rare disease in what will be pivotal year for CRISPR and gene-editing technologies.
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Other Names / Subsidiaries
- ProQR Therapeutics B.V.